News

Co-creating ethical horizons: Public attitudes and regulatory considerations for future cancer nanomedicines in clinical trials

The advancement of future cancer nanomedicines, like collective nanosystems, offers a chance to promote responsible governance by anticipating technological developments and addressing ethical issues. Collective nanosystems are large numbers of tiny nano-sized carriers that work together to find and remove cancer cells, drawing inspiration from teams of cooperative robots. Computer models and artificial intelligence can be used to enhance collective nanosystem design, aiming to accelerate targeted treatments and streamline drug development by reducing experimental time.

Bristol researchers contribute to House of Lords report on obesity and diet

"The Government needs a plan to fix our broken food system and turn the tide on the obesity public health emergency, says Lords committee.". This is the key conclusion reached by the House of Lords Food, Diet and Obesity Committee in a report published today. The report, ‘Recipe for health: a plan to fix our broken food system’, finds that obesity and diet-related disease are a public health emergency that costs society billions each year in healthcare costs and lost productivity.

ProtecT trial receives award for pioneering research demonstrating the safety of active surveillance

A study to find out the best ways of treating prostate cancer has been named the 2024 recipient of the Active Surveillance Patients International (ASPI) Special Award. The ProtecT trial, led by the Universities of Bristol and Oxford, received the award for game-changing research in the development of the active surveillance approach to managing low-risk prostate cancer. Their research has proved active monitoring in patients with lower-risk prostate cancer was as safe as aggressive treatments.